scholarly journals Dose-escalation phase I study in metastatic breast cancer patients with combination of paclitaxel and tegafur·uracil

2010 ◽  
Vol 1 (1) ◽  
pp. 45-49
Author(s):  
AKIHIKO OSAKI ◽  
SHOSHU MITSUYAMA ◽  
JUN-ICHI KUREBAYASHI ◽  
HIROSHI SONOO ◽  
REIKI NISHIMURA ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Phase I ◽  
Cancer Patients ◽  
Dose Escalation ◽  
Phase I Study ◽  
Metastatic Breast ◽  
Breast Cancer Patients

scholarly journals Phase I Study of Panobinostat (LBH589) and Letrozole in Postmenopausal Metastatic Breast Cancer Patients

2016 ◽  
Vol 16 (2) ◽  
pp. 82-86 ◽  
Author(s):  
Winston W. Tan ◽  
Jacob B. Allred ◽  
Alvaro Moreno-Aspitia ◽  
Donald W. Northfelt ◽  
James N. Ingle ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Phase I ◽  
Cancer Patients ◽  
Phase I Study ◽  
Metastatic Breast ◽  
Breast Cancer Patients

scholarly journals Phase I Study of Combination Therapy With Weekly Nanoparticle Albumin-bound Paclitaxel and Cyclophosphamide in Metastatic Breast Cancer Patients

2019 ◽  
Vol 39 (12) ◽  
pp. 6903-6907 ◽  
Author(s):  
DAISUKE OTA ◽  
SOTARO AKATSUKA ◽  
TSUNEHIRO NISHI ◽  
TAKAO KATO ◽  
MASASHI TAKEUCHI ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Combination Therapy ◽  
Phase I ◽  
Cancer Patients ◽  
Phase I Study ◽  
Metastatic Breast ◽  
Breast Cancer Patients

Anti-tumor activity of PM1183 (lurbinectedin) in combination with capecitabine in metastatic breast cancer patients: Results from a phase I trial.

2018 ◽  
Vol 36 (15_suppl) ◽  
pp. 1072-1072
Author(s):  
Ahmad Awada ◽  
Philippe Georges Aftimos ◽  
Emiliano Calvo ◽  
Valentina Boni ◽  
Victor Moreno ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Phase I ◽  
Cancer Patients ◽  
Phase I Trial ◽  
Metastatic Breast ◽  
Breast Cancer Patients ◽  
Anti Tumor Activity

scholarly journals Immunization of metastatic breast cancer patients with a fully synthetic globo H conjugate: A phase I trial

2001 ◽  
Vol 98 (6) ◽  
pp. 3270-3275 ◽  
Author(s):  
T. Gilewski ◽  
G. Ragupathi ◽  
S. Bhuta ◽  
L. J. Williams ◽  
C. Musselli ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Phase I ◽  
Cancer Patients ◽  
Phase I Trial ◽  
Metastatic Breast ◽  
Breast Cancer Patients

Tumor Burden Influences Cytotoxic T Cell Development in Metastatic Breast Cancer Patients—A Phase I/II Study

2009 ◽  
Vol 38 (8) ◽  
pp. 820-838 ◽  
Author(s):  
Stephen E. Wright ◽  
Kathleen A. Rewers-Felkins ◽  
Imelda S. Quinlin ◽  
Catherine A. Phillips ◽  
Mary Townsend ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
T Cell ◽  
Phase I ◽  
Cancer Patients ◽  
T Cell Development ◽  
Metastatic Breast ◽  
Tumor Burden ◽  
Cytotoxic T Cell ◽  
Breast Cancer Patients

Phase I study of paclitaxel in combination with cyclophosphamide and granulocyte colony-stimulating factor in metastatic breast cancer patients.

1996 ◽  
Vol 14 (1) ◽  
pp. 95-102 ◽  
Author(s):  
A W Tolcher ◽  
K H Cowan ◽  
M H Noone ◽  
A M Denicoff ◽  
D R Kohler ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Phase I ◽  
Phase I Study ◽  
Metastatic Breast ◽  
Ambulatory Setting ◽  
Granulocyte Colony Stimulating Factor ◽  
Colony Stimulating Factor ◽  
Breast Cancer Patients ◽  
Stimulating Factor

PURPOSE In vitro data suggest that prolonged exposure to paclitaxel enhances breast cancer cytotoxicity. Our objective in this phase I study was to determine the tolerability of paclitaxel administered by 72-hour continuous intravenous (i.v.) infusion (CIVI) in combination with high-dose cyclophosphamide and granulocyte colony-stimulating factor (G-CSF) in the ambulatory setting to metastatic breast cancer patients. PATIENTS AND METHODS Paclitaxel was administered over 72 hours by CIVI and cyclophosphamide was given daily by i.v. bolus on days 1, 2, and 3, followed by G-CSF every 21 days. The availability of ambulatory infusion pumps and paclitaxel-compatible tubing permitted outpatient administration. RESULTS Fifty-five patients with metastatic breast cancer who had been previously treated with a median of two prior chemotherapy regimens were entered onto the study. Dose-limiting toxicity of grade 4 neutropenia for longer than 5 days and grade 4 thrombocytopenia occurred in three of five patients treated with paclitaxel 160 mg/m2 CIVI and cyclophosphamide 3,300 mg/m2 followed by G-CSF. The maximum-tolerated dose (MTD) was paclitaxel 160 mg/m2 CIVI and cyclophosphamide 2,700 mg/m2 in divided doses with G-CSF. Nonhematologic toxicities were moderate and included diarrhea, mucositis, and arthalgias. Although hemorrhagic cystitis developed in six patients, recurrence was prevented with i.v. and oral mesna, which permitted continued outpatient delivery. One hundred seventy-four cycles were safely administered in the ambulatory setting using infusional pumps and tubing. Objective responses occurred in 23 (one complete and 22 partial) of 42 patients with bidimensionally measurable disease (55%; 95% confidence interval, 38% to 70%), with a response rate of 73% (11 of 15) seen at the highest dose levels. CONCLUSION Paclitaxel by 72-hour CIVI with daily cyclophosphamide followed by G-CSF can be administered safely in the ambulatory setting, has acceptable toxicity, and is an active regimen in the treatment of metastatic breast cancer.

Weekly Docetaxel in Pretreated Metastatic Breast Cancer Patients: A Phase I-II Study

Oncology ◽  
2005 ◽  
Vol 68 (4-6) ◽  
pp. 356-363 ◽  
Author(s):  
Cecilia Nisticò ◽  
Francesco Cognetti ◽  
Luciano Frontini ◽  
Sandro Barni ◽  
Gianluigi Ferretti ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Phase I ◽  
Cancer Patients ◽  
Metastatic Breast ◽  
Breast Cancer Patients ◽  
Weekly Docetaxel
Sign in / Sign up

Export Citation Format

Share Document